ESMO E-Learning: Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer
- To understand the different treatment paradigms for patients relapsing or progressing after first line chemotherapy with or without surgery for ovarian cancer.
- To become familiar with the experimental approaches currently being evaluated for relapsed ovarian cancer.
- To be able to apply the principles of treatment for relapsed ovarian cancer to the case histories presented.
|Title||Duration||Content||CME Points||CME Test|
|Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer||42 min.||41 slides||1||Take Test|
The treatment of ovarian cancer has progressed over the past few decades through improvements in surgery, the evolution of chemotherapy and the establishment of international co-operative groups for clinical trials in gynaecological cancer in such a way that advances can become available to patients much more rapidly. The majority of women with epithelial ovarian cancer will not be cured with initial treatment.
Taking into account the frequency of each stage of the disease and its projected relapse rate, the overall likelihood of relapse after first-line chemotherapy for all stages of disease in women with epithelial ovarian cancer is high; 80-85% for women who present with stage III or IV disease. Practice considerations for selecting the second-line medical therapies in patients with epithelial ovarian cancer are reviewed in this E-Learning module.
In this presentation, the authors discuss the management of patients with ovarian cancer who have relapsed or progressed following treatment that has included a single line of chemotherapy. The module is organised into several methodological units. In the first part, the authors present monitoring strategies in ovarian cancer patients following first-line chemotherapy given with or without surgery. In the second part they cover issues important for determining the optimal treatment paradigm, such as the treatment aims, timing of treatment, pattern of relapse, and selection of chemotherapy. In the next part, they discuss three patient cases, in particular clinical scenarios in women with localised relapse, widespread relapse, and asymptomatic relapse.
The authors also lead the audience to the spectrum of future directions in the research of chemotherapeutic combinations. They focus on the identification of biomarkers, on personalised therapy based on validated biomarkers and assessment in patient sub-populations on the basis of genetic mutations, histological subtypes and other molecular characteristics, as well as new parameters, to assess a category of response determined as "clinical benefit" in the setting of advanced disease.
The authors have reported no conflict of interest.